Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
about
Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance.227 Views of RNA: Is RNA Unique in Its Chemical Isomer Space?In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.The HBV drug entecavir - effects on HIV-1 replication and resistanceSynthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.Free Energy-Based Virtual Screening and Optimization of RNase H Inhibitors of HIV-1 Reverse Transcriptase.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.Selecting anti-HIV therapies based on a variety of genomic and clinical factors.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceDisease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse trancripatse inhibitor" backbone of highly active antiretroviral therapy in resource limited settings.Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature reviewPhysiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective.Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.
P2860
Q25256746-9A69F44D-A84D-48D1-A6CA-8F0199426ADCQ28645765-71496E80-AFEE-4F75-91C8-31C4F690E5FCQ34352006-732B60F5-B4F3-4CCC-96FD-613F7631EAD2Q34639926-368D468A-A0F3-4241-97B5-2D3E6A712F27Q36069767-4C5D5B99-D3CB-4E27-9F7E-5B0F4F18046AQ36155983-1C97DD3F-F08F-4A7A-BF65-2EEDBF0EBBE1Q36276790-5116E5A6-0200-41CE-AE06-6E46A0929BD9Q36425068-3D9EA622-1951-4034-BC00-F64D81589389Q36950131-6E56686A-C742-4B27-915B-32F0E319902FQ37013364-ED69FC52-002A-4CBD-936F-3EAD096538EFQ37283246-D31112CA-1236-4987-9A9A-1A1D51B39470Q37288671-0230635C-3FEB-45EC-8768-51BBEA889084Q37381677-6DB94E90-24AD-410A-8E6E-1448A298C268Q37410853-D667C195-FE47-4DA7-A52E-AA68591909B2Q38263521-9864167A-BC4C-4ACB-8F49-693F8B97B2A6Q40432241-1EA4E76F-E929-46A6-80B4-E546C2AFBB20Q41066820-4B55ECB9-C99D-499B-8204-5135F3850AB5Q41766427-A892184F-08EB-4153-9E95-0CF8BE0B03ABQ41820283-CB98189E-DB8F-4AB5-9C78-BB772503AF31Q42042678-8D40B071-1DD4-4350-BF9A-0EFD7EED445CQ42178078-BE85BBBD-E0B8-4419-B3AA-3CD03598E5F9Q42549637-BE47696A-3B2F-4003-B039-329795CC1489Q42797684-AE9CC381-6287-4E79-9E81-E3EED325AE2D
P2860
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@ast
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@en
type
label
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@ast
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@en
prefLabel
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@ast
Nucleoside and nucleotide anal ...... of antiretroviral resistance.
@en
P2093
P1433
P1476
Nucleoside and nucleotide anal ...... w of antiretroviral resistance
@en
P2093
Douglas D Richman
Ernest R Lanier
Joel E Gallant
Mark A Wainberg
Marty St Clair
Nancy S Shulman
Nicholas S Hellmann
Peter Z Gerondelis
Richard H Haubrich
P304
P577
2003-12-01T00:00:00Z